Jaguar Animal Health Exhibits Neonorm Foal at American Association of Equine Practitioners Annual Convention
Jaguar Also Hosted a Dinner Discussion Gathering During AAEP with
Equine Veterinarian Opinion Leaders in Support of the Company’s Clinical
Development Efforts
SAN FRANCISCO–(BUSINESS WIRE)–Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health
company focused on developing and commercializing first-in-class
gastrointestinal products for companion and production animals, foals,
and high value horses, today announced that it exhibited its Neonorm™
Foal product in Henry Schein’s booth at the American Association of
Equine Practitioners (AAEP) Annual Convention and Trade Show from
December 4th – 6th in Orlando. Jaguar also hosted
a dinner gathering during AAEP with leading equine veterinarians in
support of the Company’s ongoing equine-focused clinical development
efforts.
Founded in 1954, the AAEP has 9,000 members worldwide. The AAEP’s Annual
Convention and Trade Show is the world’s largest meeting dedicated to
the equine veterinary profession, attended annually by an estimated
3,000 practitioners, students and technicians and featuring more than
300 exhibiting companies.
Neonorm™ Foal is a natural, clinically-tested, non-drug
product designed for use as an anti-diarrheal in foals. The product,
which acts locally in the gut and is minimally absorbed systemically,
contains a proprietary, standardized botanical extract derived from the Croton
lechleri tree, which is sustainably harvested.
Jaguar’s dinner gathering of equine opinion leaders took place in
Orlando this past Sunday and was attended by 16 prominent equine
veterinarians in addition to members of the Company’s management and
clinical development teams. Discussion centered on the potential use of
Neonorm™ to address diarrhea in adult horses, and Jaguar’s
ongoing clinical development plans for Equilevia™, the
Company’s prescription drug product candidate for treatment of
gastrointestinal ulcers in horses.
Diarrhea is one of the most common clinical complaints in foals,
especially within the first 30 days of life, and to the Company’s
knowledge there are currently no commercially available products with
anti-secretory properties for foals. The crippling effects of
dehydration that often occur as a result of secretory diarrhea in foals
can manifest quickly, precipitate adverse health effects and result in
death.
“The addressable market for Neonorm™ would be significantly
expanded if we’re able to demonstrate that the product can be used to
address diarrhea in adult horses,” stated Lisa Conte, Jaguar’s president
and CEO. “As one of the equine veterinarians who attended our dinner
gathering on December 4th commented, ‘[Chronic diarrhea in
healthy adult horses] is a syndrome that you won’t read much about in
the literature, but it’s well known amongst veterinarians. It drives
owners crazy.’”
In November 2015, Jaguar announced the results of an initial
proof-of-concept study (NEO101) which involved 60 foals that received
Neonorm™ Foal in combination with a third-party probiotic. In
December 2015, Jaguar announced positive results for an exploratory,
investigator-initiated follow-up study (ARG102) which assessed the
safety and performance of Neonorm™ Foal, without inclusion of
a probiotic, in pre-weaned foals with watery diarrhea. The results of a
meta-analysis between the two studies identified 85% of foals treated
with Neonorm™ Foal in ARG102 as clinical responders, compared
with 35% of placebo-treated foals in NEO101, and resolution of diarrhea
was observed in 85% of foals treated with Neonorm™ Foal in
ARG102 versus 41% of placebo-treated foals in NEO101.
Dr. Siobhan McAuliffe, MVB, DACVIM, the Argentina-based investigator who
initiated the follow-up study, commented, “Diarrhea is the most common
ailment of foals. A foal with diarrhea can lose a significant volume of
water and electrolytes each day. The dehydration that results can prove
fatal, or it can lead to other serious problems such as kidney failure
and cardiac arrhythmias. For me the most resounding endorsement of the
product was how quickly we enrolled foals in the study. Once the word
got out that we had a product that really worked, we were turning away
foals! To this day I still have people calling me looking for the
product.”
Jaguar launched Neonorm Foal in early 2016 with a nationwide campaign
offering samples. The reception among users of the product has been
overwhelmingly positive, leading to a number of favorable posts from
users on Jaguar’s Facebook page, located at www.facebook.com/jaguaranimalhealth.
Foaling season in the northern hemisphere takes place from January to
July. Jaguar estimates that approximately 300,000 to 360,000 foals are
born in the US each year. Data from the American Horse Council states
that there are currently 9.2 million horses in the U.S., a population
that includes 844,531 race horses, more than 2.7 million show horses,
and more than 3.9 million recreational horses. Data from the Food and
Agriculture Organization of the United Nations indicate that there were
approximately 5.7 million horses in Europe in 2013 and nearly 60 million
horses in 2013 worldwide.
About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused on
developing and commercializing first-in-class gastrointestinal products
for companion and production animals, foals, and high value horses.
Canalevia™ is Jaguar’s lead prescription drug product
candidate, intended for the treatment of various forms of diarrhea in
dogs. Equilevia™ (formerly referred to as SB-300) is Jaguar’s
prescription drug product candidate for the treatment of
gastrointestinal ulcers in horses. Canalevia™ and Equilevia™
contain ingredients isolated and purified from the Croton lechleri
tree, which is sustainably harvested. Neonorm™ Calf and
Neonorm™ Foal are the Company’s lead non-prescription
products. Neonorm™ is a standardized botanical extract
derived from the Croton lechleri tree. Canalevia™ and
Neonorm™ are distinct products that act at the same last step
in a physiological pathway generally present in mammals. Jaguar has nine
active investigational new animal drug applications, or INADs, filed
with the FDA and intends to develop species-specific formulations of
Neonorm™ in six additional target species, formulations of
Equilevia™ in horses, and Canalevia™ for cats and
dogs.
For more information, please visit www.jaguaranimalhealth.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking
statements” within the meaning of section 27A of the Securities Act of
1933 and section 21E of the Securities Exchange Act of 1934. These
include statements regarding the Company’s belief that the addressable
market for Neonorm™ would be significantly expanded if Jaguar
is able to demonstrate that the product can be used to address diarrhea
in adult horses, and Jaguar’s intention to develop species-specific
formulations of Neonorm™ in six additional target species,
formulations of Equilevia™ in horses, and Canalevia™
for cats and dogs. In some cases, you can identify forward-looking
statements by terms such as “may,” “will,” “should,” “expect,” “plan,”
“aim,” “anticipate,” “could,” “intend,” “target,” “project,”
“contemplate,” “believe,” “estimate,” “predict,” “potential” or
“continue” or the negative of these terms or other similar expressions.
The forward-looking statements in this release are only predictions.
Jaguar has based these forward-looking statements largely on its current
expectations and projections about future events. These forward-looking
statements speak only as of the date of this release and are subject to
a number of risks, uncertainties and assumptions, some of which cannot
be predicted or quantified and some of which are beyond Jaguar’s
control. Except as required by applicable law, Jaguar does not plan to
publicly update or revise any forward-looking statements contained
herein, whether as a result of any new information, future events,
changed circumstances or otherwise.
Jaguar-JAGX
Contacts
KCSA Strategic Communications
Garth Russell, 212-896-1250
grussell@kcsa.com
